PMID- 20022264
OWN - NLM
STAT- MEDLINE
DCOM- 20100527
LR  - 20220330
IS  - 1557-3117 (Electronic)
IS  - 1053-2498 (Linking)
VI  - 29
IP  - 2
DP  - 2010 Feb
TI  - Exercise improvement and plasma biomarker changes with intravenous treprostinil 
      therapy for pulmonary arterial hypertension: a placebo-controlled trial.
PG  - 137-49
LID - 10.1016/j.healun.2009.09.005 [doi]
AB  - BACKGROUND: Pulmonary arterial hypertension (PAH) remains a poorly understood and 
      frequently lethal disease with few treatment options. METHODS: We conducted a 
      placebo-controlled trial of intravenous treprostinil, a prostacyclin analog, in 
      treatment-naive PAH patients. During 12 weeks of treatment with treprostinil or 
      placebo, we quantified 6-minute walk distance (6MW), clinical symptoms and 11 
      cytokines/growth factors. RESULTS: Forty-two of 44 study patients had 
      idiopathic/familial PAH in New York Heart Association (NYHA) Class III. 
      Treprostinil increased 6MW by a placebo-corrected median of 83 meters (p = 0.008; 
      mean increase 93 +/- 42 meters), reduced Borg score by a median 2.0 units (p = 
      0.02), and improved NYHA class by a median of 1.0 (p = 0.02). There was a trend 
      toward improved survival with treprostinil (p = 0.051). Baseline plasma 
      angiopoietin-2 (Ang-2), vascular endothelial growth factor (VEGF), matrix 
      metalloproteinase-9 (MMP-9) and platelet-derived growth factor (PDGF) were 
      elevated compared with reported normal ranges. Treatment with treprostinil was 
      associated with decreased Ang-2 levels. Improvement in 6MW distance after 
      treatment was associated with reductions in Ang-2 and MMP-9 levels. Most of the 
      cytokines and growth factors studied were not abnormal with disease nor did they 
      change with treatment. CONCLUSIONS: We conclude that treprostinil treatment 
      significantly improved exercise capacity, dyspnea and functional class. Several 
      plasma proteins that might track disease were abnormal at baseline, and changes 
      were associated with improved exercise capacity.
FAU - Hiremath, Jagdish
AU  - Hiremath J
AD  - Ruby Hall Clinic, Pune, India.
FAU - Thanikachalam, Sadagopa
AU  - Thanikachalam S
FAU - Parikh, Keyur
AU  - Parikh K
FAU - Shanmugasundaram, Somasundaram
AU  - Shanmugasundaram S
FAU - Bangera, Sudhakar
AU  - Bangera S
FAU - Shapiro, Leland
AU  - Shapiro L
FAU - Pott, Gregory B
AU  - Pott GB
FAU - Vnencak-Jones, Cindy L
AU  - Vnencak-Jones CL
FAU - Arneson, Carl
AU  - Arneson C
FAU - Wade, Michael
AU  - Wade M
FAU - White, R James
AU  - White RJ
CN  - TRUST Study Group
LA  - eng
SI  - ClinicalTrials.gov/NCT00494533
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Heart Lung Transplant
JT  - The Journal of heart and lung transplantation : the official publication of the 
      International Society for Heart Transplantation
JID - 9102703
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Biomarkers)
RN  - DCR9Z582X0 (Epoprostenol)
RN  - RUM6K67ESG (treprostinil)
SB  - IM
CIN - J Heart Lung Transplant. 2010 Feb;29(2):157-8. PMID: 20113908
CIN - J Heart Lung Transplant. 2010 Jul;29(7):825-6. PMID: 20456982
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Antihypertensive Agents/*administration & dosage
MH  - Biomarkers/blood
MH  - Double-Blind Method
MH  - Epoprostenol/administration & dosage/*analogs & derivatives
MH  - Exercise
MH  - Female
MH  - Humans
MH  - Hypertension, Pulmonary/*drug therapy
MH  - Infusions, Intravenous
MH  - Male
MH  - Middle Aged
MH  - Physical Endurance/*drug effects
MH  - Severity of Illness Index
MH  - Treatment Outcome
MH  - Walking
FIR - Brundage, B
IR  - Brundage B
FIR - Langleben, D
IR  - Langleben D
FIR - Rich, S
IR  - Rich S
FIR - Koch, G
IR  - Koch G
FIR - Wenger, T
IR  - Wenger T
FIR - Kerkar, P G
IR  - Kerkar PG
FIR - Jain, P R K
IR  - Jain PR
FIR - Suresh, P V
IR  - Suresh PV
FIR - Babu, R
IR  - Babu R
FIR - Kumble, Y
IR  - Kumble Y
FIR - Raghu, C
IR  - Raghu C
FIR - Ramachandra, V S
IR  - Ramachandra VS
FIR - Ramachandran, P
IR  - Ramachandran P
FIR - Tyagi, S
IR  - Tyagi S
FIR - Ramasubban, S
IR  - Ramasubban S
FIR - Kumar, M V
IR  - Kumar MV
FIR - Gheyee, S W
IR  - Gheyee SW
FIR - Kelen, R
IR  - Kelen R
FIR - McSwain, S
IR  - McSwain S
FIR - Jeffs, R
IR  - Jeffs R
FIR - Bunce, D
IR  - Bunce D
FIR - Sigman, J
IR  - Sigman J
FIR - DellaMaestra, W
IR  - DellaMaestra W
FIR - Greene, C
IR  - Greene C
EDAT- 2009/12/22 06:00
MHDA- 2010/05/28 06:00
CRDT- 2009/12/22 06:00
PHST- 2009/08/03 00:00 [received]
PHST- 2009/09/04 00:00 [revised]
PHST- 2009/09/05 00:00 [accepted]
PHST- 2009/12/22 06:00 [entrez]
PHST- 2009/12/22 06:00 [pubmed]
PHST- 2010/05/28 06:00 [medline]
AID - S1053-2498(09)00781-5 [pii]
AID - 10.1016/j.healun.2009.09.005 [doi]
PST - ppublish
SO  - J Heart Lung Transplant. 2010 Feb;29(2):137-49. doi: 
      10.1016/j.healun.2009.09.005.